US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OS Therapies

1.90

+0.03001.60%

Post-market: 1.84-0.0600-3.16%19:31 EDT

Volume:207.94K

Turnover:389.44K

Market Cap:63.71M

PE:-2.57

High:1.92

Open:1.90

Low:1.85

Close:1.87

52wk High:7.00

52wk Low:1.12

Shares:33.53M

Float Shares:23.38M

Volume Ratio:0.51

T/O Rate:0.89%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7392

EPS(LYR):-0.8795

ROE:--

ROA:-163.50%

PB:12.89

PE(LYR):-2.16

Loading ...

Overview Company News Filings

OS Therapies Inc. to Participate in Cantor Global Healthcare Conference 2025

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Inc. Announces Upcoming BLA Submission for OST-HER2 Following Positive FDA Phase 2 Meeting for Metastatic Osteosarcoma Program

OS Therapies Inc. Announces FDA End of Phase 2 Meeting Update for OST-HER2 in Recurrent Pulmonary Metastatic Osteosarcoma

OS Therapies Is Maintained at Buy by D. Boral Capital

Os Therapies Inc - on Aug 25, Terminates Equity Purchase Agreement With Square Gate - SEC Filing

THOMSON REUTERS

OS Therapies Terminates Equity Purchase Agreement

MT Newswires Live

OS Therapies Inc. Announces Date for 2025 Annual Stockholders Meeting

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Inc. Reports Increased Q2 2025 Net Operating Loss of $4.537 Million; EPS Improves to $0.19 Compared to $0.26 in Q2 2024

OS Therapies Q2 EPS $(0.19) Misses $(0.12) Estimate

OS Therapies Inc. Secures Patent for Innovative Listeria Cancer Immunotherapy Manufacturing Process, Ensuring Exclusivity Through 2040

OS Therapies Inc. Amends Bylaws to Adjust Quorum Requirement

OS Therapies Inc. to Report Second Quarter 2025 Financial Results

OS Therapies Inc. Advances OST-HER2 with UK MHRA Positive Feedback and Submits ILAP Request for Osteosarcoma Treatment Approval

OS Therapies Inc. Announces Plans for Biologics Licensing, Strategic Alternatives, AI-Driven Product Modeling, and Closing Prostate Cancer Study

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Inc. Schedules Key FDA Meeting for OST-HER2 Osteosarcoma Program, Advances Toward Global Regulatory Approvals

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Inc. Granted End of Phase 2 Meeting by FDA for OST-HER2 Program in Osteosarcoma Prevention

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OSTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.9,"timestamp":1761768000000,"preClose":1.87,"halted":0,"volume":207941,"hourTrading":{"tag":"盘后","latestPrice":1.84,"preClose":1.9,"latestTime":"19:31 EDT","volume":7539,"amount":13934.525,"timestamp":1761780663743},"delay":0,"floatShares":23381200,"shares":33532500,"eps":-0.739242,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"10-29 16:00:00 EDT","open":1.9,"high":1.916,"low":1.85,"amount":389436.9993545,"amplitude":0.035294,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.739242,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1761811200000},"marketStatusCode":0,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.87,"preHourTrading":{"tag":"盘前","latestPrice":1.88,"preClose":1.87,"latestTime":"09:26 EDT","volume":401,"amount":755.3549982999999,"timestamp":1761744366055},"postHourTrading":{"tag":"盘后","latestPrice":1.84,"preClose":1.9,"latestTime":"19:31 EDT","volume":7539,"amount":13934.525,"timestamp":1761780663743},"volumeRatio":0.509451},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":23381200,"roa":"-163.50%","roe":"--","lyrEps":-0.879526,"volumeRatio":0.509451,"shares":33532500,"dividePrice":0,"high":1.916,"amplitude":0.035294,"preClose":1.87,"low":1.85,"week52Low":1.12,"pbRate":"12.89","week52High":7,"institutionHeld":0,"latestPrice":1.9,"eps":-0.739242,"divideRate":0,"volume":207941,"delay":0,"ttmEps":-0.739242,"open":1.9,"prevYearClose":4.28,"prevWeekClose":1.89,"prevMonthClose":1.96,"prevQuarterClose":1.96,"fiveDayClose":1.83,"twentyDayClose":2,"sixtyDayClose":1.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2025-10-28","current":-2.5702,"percent":0.726984,"low":-14.897496,"twenty":-10.047148,"median":-5.177924,"eighty":-4.425694,"high":-2.731469,"avg":-6.846844,"sd":3.172391,"marketCap":65723680},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762},{"date":"2025-06-20","current":-4.525147,"twenty":-11.288606,"median":-6.448552,"eighty":-4.525147,"marketCap":51137808},{"date":"2025-06-27","current":-4.500284,"twenty":-11.257432,"median":-6.245836,"eighty":-4.450557,"marketCap":50856831},{"date":"2025-07-03","current":-4.804944,"twenty":-11.153916,"median":-6.178419,"eighty":-4.480042,"marketCap":54299732},{"date":"2025-07-11","current":-4.384839,"twenty":-11.071717,"median":-6.001438,"eighty":-4.444649,"marketCap":49552214},{"date":"2025-07-18","current":-4.411096,"twenty":-11.057637,"median":-5.848373,"eighty":-4.413618,"marketCap":49848934},{"date":"2025-07-25","current":-5.118748,"twenty":-11.006503,"median":-5.726085,"eighty":-4.413618,"marketCap":57845975},{"date":"2025-08-01","current":-5.266689,"twenty":-10.886225,"median":-5.658739,"eighty":-4.423405,"marketCap":59517824},{"date":"2025-08-08","current":-5.177924,"twenty":-10.817778,"median":-5.632611,"eighty":-4.43502,"marketCap":58514715},{"date":"2025-08-15","current":-6.36145,"twenty":-10.649839,"median":-5.600996,"eighty":-4.43838,"marketCap":71889507},{"date":"2025-08-22","current":-5.360009,"twenty":-10.610453,"median":-5.567348,"eighty":-4.444649,"marketCap":76540639},{"date":"2025-08-29","current":-5.047341,"twenty":-10.610453,"median":-5.538676,"eighty":-4.449676,"marketCap":72075768},{"date":"2025-09-05","current":-4.667674,"twenty":-10.601601,"median":-5.456641,"eighty":-4.458388,"marketCap":66654139},{"date":"2025-09-12","current":-5.119065,"twenty":-10.582903,"median":-5.4212,"eighty":-4.477891,"marketCap":73099984},{"date":"2025-09-19","current":-4.897461,"twenty":-10.460155,"median":-5.370028,"eighty":-4.495136,"marketCap":69935483},{"date":"2025-09-26","current":-4.675856,"twenty":-10.329392,"median":-5.362697,"eighty":-4.515202,"marketCap":66770981},{"date":"2025-10-03","current":-4.409931,"twenty":-10.231142,"median":-5.325865,"eighty":-4.459866,"marketCap":62973579},{"date":"2025-10-10","current":-4.520733,"twenty":-10.170508,"median":-5.292169,"eighty":-4.471291,"marketCap":64555830},{"date":"2025-10-17","current":-4.099684,"twenty":-10.138159,"median":-5.266689,"eighty":-4.443146,"marketCap":58543277},{"date":"2025-10-24","current":-4.250282,"twenty":-10.078376,"median":-5.177924,"eighty":-4.421116,"marketCap":60693806},{"date":"2025-10-28","current":-4.602516,"twenty":-10.047148,"median":-5.177924,"eighty":-4.425694,"marketCap":65723680}],"updateTime":1761797332458},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564398811","title":"OS Therapies Inc. to Participate in Cantor Global Healthcare Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398811","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398811?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:40","pubTimestamp":1756899655,"startTime":"0","endTime":"0","summary":"OS Therapies Inc., a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company will provide a pre-recorded presentation for conference participants and engage in meetings with institutional investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on September 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL2z5sFw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2564480045","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2564480045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564480045?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:13","pubTimestamp":1756818780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 02, 2025 09:13 ET (13:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2564450801","title":"OS Therapies Inc. Announces Upcoming BLA Submission for OST-HER2 Following Positive FDA Phase 2 Meeting for Metastatic Osteosarcoma Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2564450801","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564450801?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:40","pubTimestamp":1756813258,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Announces Upcoming BLA Submission for OST-HER2 Following Positive FDA Phase 2 Meeting for Metastatic Osteosarcoma Program. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on September 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL56bmPl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2562328727","title":"OS Therapies Inc. Announces FDA End of Phase 2 Meeting Update for OST-HER2 in Recurrent Pulmonary Metastatic Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2562328727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562328727?lang=en_us&edition=fundamental","pubTime":"2025-08-28 04:02","pubTimestamp":1756324927,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced that it will provide an update on the regulatory path forward for its OST-HER2 treatment, aimed at recurrent, fully resected, pulmonary metastatic osteosarcoma. This update will follow a constructive End of Phase 2 Meeting with the US Food & Drug Administration. The details of this meeting and the future steps towards approval will be discussed with stakeholders on September 2, 2025. The company is expected to share insights into the outcomes of the meeting and the anticipated next steps in the regulatory process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on August 27, 2025, and is solely responsible for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL3yWHss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2562869749","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2562869749","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562869749?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:30","pubTimestamp":1756297800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 27, 2025 08:30 ET (12:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2562821277","title":"Os Therapies Inc - on Aug 25, Terminates Equity Purchase Agreement With Square Gate - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2562821277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562821277?lang=en_us&edition=fundamental","pubTime":"2025-08-26 18:16","pubTimestamp":1756203408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nFWN3UI0C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2562028783","title":"OS Therapies Terminates Equity Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2562028783","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562028783?lang=en_us&edition=fundamental","pubTime":"2025-08-26 16:07","pubTimestamp":1756195626,"startTime":"0","endTime":"0","summary":"OS Therapies  said late Monday it has terminated its equity purchase agreement with Square Gate Capital Master Fund, effective Aug. 26.Chairman and Chief Executive Paul Romness said its recent warrant exercise inducement and exchange offering provided the company with $4.2 million in gross proceeds to fund operations into mid-2026.\"[O]ur projected monthly burn in the second half of 2025 is significantly less than it was in the first half of 2025,\" he said.Shares of the cancer-focused biotech company were up 3.7% in after-market activity.Price: 2.27, Change: +0.08, Percent Change: +3.65","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQR","BK4139","OSTX","BK4215","BK4585","BK4588"],"gpt_icon":0},{"id":"2562278440","title":"OS Therapies Inc. Announces Date for 2025 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2562278440","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562278440?lang=en_us&edition=fundamental","pubTime":"2025-08-26 05:15","pubTimestamp":1756156528,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated is set to hold its 2025 Annual Meeting of Stockholders on October 14, 2025. The meeting will be conducted in a virtual format. The Notice of Annual Meeting of Stockholders and Proxy Statement outlines the proposals to be considered and voted upon at this meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL3cysXn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2560767109","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2560767109","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560767109?lang=en_us&edition=fundamental","pubTime":"2025-08-20 21:28","pubTimestamp":1755696480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 20, 2025 09:28 ET (13:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2560198122","title":"OS Therapies Inc. Reports Increased Q2 2025 Net Operating Loss of $4.537 Million; EPS Improves to $0.19 Compared to $0.26 in Q2 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2560198122","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560198122?lang=en_us&edition=fundamental","pubTime":"2025-08-19 18:51","pubTimestamp":1755600686,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Reports Increased Q2 2025 Net Operating Loss of $4.537 Million; EPS Improves to $0.19 Compared to $0.26 in Q2 2024. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL5LS6RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2560672971","title":"OS Therapies Q2 EPS $(0.19) Misses $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2560672971","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560672971?lang=en_us&edition=fundamental","pubTime":"2025-08-19 18:07","pubTimestamp":1755598073,"startTime":"0","endTime":"0","summary":"OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 65.22 percent. This is a 26.92 percent increase over losses of $(0.26) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47203674/os-therapies-q2-eps-0-19-misses-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2560177167","title":"OS Therapies Inc. Secures Patent for Innovative Listeria Cancer Immunotherapy Manufacturing Process, Ensuring Exclusivity Through 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=2560177167","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560177167?lang=en_us&edition=fundamental","pubTime":"2025-08-19 18:01","pubTimestamp":1755597687,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Secures Patent for Innovative Listeria Cancer Immunotherapy Manufacturing Process, Ensuring Exclusivity Through 2040. OS Therapies Inc. has been granted a new patent by the U.S. Patent & Trademark Office, securing exclusivity for its innovative commercial manufacturing process for the listeria cancer immunotherapy platform until 2040. This patent grant marks a significant milestone in the company's efforts to advance its cancer immunotherapy initiatives, providing a foundation for continued development and potential market presence.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on August 19, 2025, and is solely responsible","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL8xYQgp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2559450019","title":"OS Therapies Inc. Amends Bylaws to Adjust Quorum Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2559450019","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559450019?lang=en_us&edition=fundamental","pubTime":"2025-08-16 04:06","pubTimestamp":1755288379,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced an amendment to its bylaws, approved by the Board of Directors on August 15, 2025. The amendment changes the quorum requirement for stockholder meetings to one-third of the voting power of outstanding shares entitled to vote, either present in person or represented by proxy. This adjustment aims to streamline decision-making processes during such meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDLbDPkqj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2559967524","title":"OS Therapies Inc. to Report Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2559967524","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559967524?lang=en_us&edition=fundamental","pubTime":"2025-08-15 05:45","pubTimestamp":1755207924,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. will report its second quarter 2025 financial results on Tuesday, August 19, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on August 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL2bTDFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2557556299","title":"OS Therapies Inc. Advances OST-HER2 with UK MHRA Positive Feedback and Submits ILAP Request for Osteosarcoma Treatment Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2557556299","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557556299?lang=en_us&edition=fundamental","pubTime":"2025-08-07 18:12","pubTimestamp":1754561562,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Advances OST-HER2 with UK MHRA Positive Feedback and Submits ILAP Request for Osteosarcoma Treatment Approval. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on August 07, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL1sVvQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OS Therapies Inc. Advances OST-HER2 with UK MHRA Positive Feedback and Submits ILAP Request for Osteosarcoma Treatment Approval","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2551183477","title":"OS Therapies Inc. Announces Plans for Biologics Licensing, Strategic Alternatives, AI-Driven Product Modeling, and Closing Prostate Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2551183477","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551183477?lang=en_us&edition=fundamental","pubTime":"2025-07-14 19:41","pubTimestamp":1752493265,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Announces Plans for Biologics Licensing, Strategic Alternatives, AI-Driven Product Modeling, and Closing Prostate Cancer Study. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on July 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL3P7lMx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2551880531","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2551880531","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551880531?lang=en_us&edition=fundamental","pubTime":"2025-07-14 19:18","pubTimestamp":1752491880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 14, 2025 07:18 ET (11:18 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2550420306","title":"OS Therapies Inc. Schedules Key FDA Meeting for OST-HER2 Osteosarcoma Program, Advances Toward Global Regulatory Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=2550420306","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550420306?lang=en_us&edition=fundamental","pubTime":"2025-07-10 19:41","pubTimestamp":1752147663,"startTime":"0","endTime":"0","summary":"OS Therapies Inc., a clinical-stage biopharmaceutical company, has announced significant progress in its regulatory review efforts for OST-HER2, a treatment targeting recurrent, pulmonary metastatic osteosarcoma. The company is set to meet with the US Food & Drug Administration  on August 27, 2025, to discuss the clinical data from its Phase 2 program and seek alignment for a rolling review Biologics Licensing Application under the FDA's Accelerated Approval Program. Additionally, OS Therapies has scheduled Scientific Advice Meetings with global regulators, including the European Medicines Agency, as part of its strategy to obtain a Centralized Marketing Authorization in the EU and a Conditional Marketing Authorization in the UK. These steps are crucial for advancing OST-HER2 towards regulatory approval and potential commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL2r2F8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2548044338","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2548044338","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548044338?lang=en_us&edition=fundamental","pubTime":"2025-07-03 20:34","pubTimestamp":1751546040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 03, 2025 08:34 ET (12:34 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2548094498","title":"OS Therapies Inc. Granted End of Phase 2 Meeting by FDA for OST-HER2 Program in Osteosarcoma Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2548094498","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548094498?lang=en_us&edition=fundamental","pubTime":"2025-07-03 19:40","pubTimestamp":1751542817,"startTime":"0","endTime":"0","summary":"OS Therapies Inc., a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, has been granted an End of Phase 2 Meeting by the United States Food & Drug Administration  for its OST-HER2 program. This program focuses on the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. The meeting, anticipated for the third quarter of 2025, marks a significant milestone in the drug's development process. OS Therapies plans to seek FDA alignment to initiate a Rolling Review process for the Biologics Licensing Application  submission of OST-HER2. This approach allows for submission of completed sections of the BLA for FDA review, potentially expediting the approval timeline. The OST-HER2 program has already received FDA Orphan Disease Designation, Fast Track, and Rare Pediatric Disease Designation. If the company secures Accelerated Approval by September 30, 2026, it may receive a Priority Review Voucher, which it intends to sell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL51sQGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":57,"code":"91000000","status":"200"}]}}